Ballentine Partners, LLC Bei Gene, Ltd. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Ballentine Partners, LLC holds 752 shares of BGNE stock, worth $170,485. This represents 0.0% of its overall portfolio holdings.
Number of Shares
752Holding current value
$170,485% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
301Shares Held
30.4MCall Options Held
147KPut Options Held
195K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion16.25% of portfolio
-
Primecap Management CO Pasadena, CA5.08MShares$1.15 Billion0.91% of portfolio
-
Capital International Investors Los Angeles, CA5.05MShares$1.14 Billion0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.63MShares$370 Million0.06% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.05% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...